Eisai Announces independent development and commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC)

CAR-T Digest - August 2020

01 July 2024: Eisai Announces independent development and commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC)

Eisai and Bristol Myers Squibb are ending their $650 million collaboration on the ADC farletuzumab ecteribulin (FZEC) due to BMS’s portfolio prioritization efforts.
FZEC, targeting FRα, consists of farletuzumab, eribulin, and a chemical linker, demonstrating a bystander effect in preclinical studies. Eisai and BMS entered into a co-development deal for FZEC in 2021
Eisai now has full ownership of FZEC and will independently advance its development with accelerated priority.
Eisai plans to refund part of the unused portion of the $200 million received from BMS for R&D expenses.
The ADC market is competitive and growing, with recent significant partnerships like BioNTech’s deal with Duality Biologics and Bristol Myers’ agreement with Tubulis reflecting industry dynamic